Pih

Quick links to important sections

Pih

Method of action: Antihypertensive

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pih

Property Description
Active ingredient Labetalol Hydrochloride
Form Tablet and Solution for Injection
Pharmacological class Combined Alpha- and Beta-Blocker
Common use Management of Hypertension
Origin Synthetic chemical entity

What is Pih and What Type of Medicine is it?

Pih is a prescription medicine containing the synthetic active substance Labetalol Hydrochloride, and it is formally classified as an Antihypertensive Agent. Pih belongs to the unique pharmacological class of a Combined Alpha- and Beta-Blocker, which means the single-ingredient substance acts on two distinct types of adrenergic receptors in the body. This dual mechanism is a property clinically recognized for its differentiated utility in managing elevated blood pressure.

Composition and Available Forms of Pih

The therapeutic effect of Pih is concentrated in the single active ingredient, Labetalol. Pih is consistently manufactured to be available in two distinct dosage forms: the oral tablet and a solution for intravenous injection. The availability of both the tablet and the injection highlights Pih's specialized positioning for both long-term management via the oral route and acute control via the intravenous route. Formulations of this substance are approved for these uses.

What is the General Purpose of Taking Pih?

The general purpose of taking Pih is to achieve a stable and sustained lowering of blood pressure, which is the fundamental goal in the management of hypertension. This therapeutic objective is accomplished through the drug's combined effects: the alpha-blocking action helps widen blood vessels, and the beta-blocking action helps decrease the force and rate of heart contractions. This synchronization of actions provides the necessary approach to controlling systemic pressure.

What side effects are possible with Pih?

Possible Side Effects and Safety Information for Pih

This information describes the possible side effects and safety considerations for Pih, based on official regulatory documentation.

Adverse Reaction Classification

Official regulatory bodies classify adverse reactions by frequency, allowing patients to understand the documented probability of experiencing a side effect. These classifications are defined as:

Frequency Category Documented Incidence
Very Common Occurs in 1 in 10 patients or more
Common Occurs in less than 1 in 10 but more than 1 in 100 patients
Uncommon Occurs in less than 1 in 100 but more than 1 in 1,000 patients
Rare Occurs in less than 1 in 1,000 but more than 1 in 10,000 patients
Not Known Cannot be estimated from the available data (typically post-marketing reports)

Adverse reactions are also categorized by the System-Organ Class (SOC) affected, such as Nervous System Disorders, Gastrointestinal Disorders, or Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Safety Constraints

The regulatory label documents specific Serious Adverse Reactions that are rare but clinically critical, which may include systemic hypersensitivity reactions or specific organ injury. The label specifies official Contraindications and Restrictions for use, such as:

  • A documented history of hypersensitivity to Pih.
  • Use in patients with severe hepatic or renal impairment.
  • High-level warnings regarding specific safety concerns, such as the potential for cardiac rhythm changes (e.g., QT interval prolongation), requiring clinical monitoring as outlined in the official documentation.

Population and Time-Related Safety

Population-specific statements apply to groups where risks may differ, such as patients with organ impairment or during pregnancy and lactation. Furthermore, the label notes any time-related patterns, such as adverse reactions that are documented to occur more frequently during the initial phase of therapy.

Overdose and Emergency Response

Pih Overdose and When to Seek Help

Overdose involving Pih (Labetalol Hydrochloride) is officially documented in regulatory information as potentially leading to severe physiological manifestations. The documented clinical presentations primarily involve the cardiovascular system, including excessive hypotension (posture sensitive low blood pressure) and profound excessive bradycardia (slow heart rate). Other signs documented in official labeling include dizziness, fainting, and difficulties related to the respiratory and central nervous systems, such as bronchospasm, seizures, and difficulty breathing.

Documented Severe Outcomes Required Emergency Actions
Excessive Hypotension, Excessive Bradycardia Seek immediate medical attention.
Cardiac Failure, Bronchospasm Call emergency services (911).
Seizures Contact the poison control helpline.

Regulators mandate immediate action when severe clinical signs are present. Urgent medical help must be sought if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The official prescribing information details management procedures, including immediate physical steps such as placing the patient supine and raising their legs to improve circulation.

The profile notes that no specific antidote is known. However, the regulatory documents specify pharmacological interventions, including glucagon for severe refractory cases of hypotension or bradycardia, and vasopressors for sustained low blood pressure. The documentation also states that procedures such as hemodialysis do not remove a significant amount of the drug from circulation.

Therapeutic Uses of Pih

What Pih Treats: Main Uses and Benefits

The primary role of Pih (Labetalol) is to address symptoms related to heightened physiological activity, specifically high blood pressure, and it is relevant across conditions characterized by periods of heightened symptoms. The medication is commonly used to help with managing various forms of hypertension.

Pih is considered relevant in contexts where additional management of discomfort is required, playing a role in managing chronic essential hypertension in adult patients. It is also used in acute clinical settings to support the controlled reduction of severe blood pressure elevation. Furthermore, the medication is commonly used across conditions presenting with acute episodes, notably Hypertension of Pregnancy including Preeclampsia, and for blood pressure related to specific physiological stresses like Sympathomimetic Toxicity.

Quick Fact: Supports Management of Severe Blood Pressure Elevation

By providing sustained lowering and control of high blood pressure, this therapy assists with maintaining a sense of stability when symptoms are more noticeable, helping to ease the overall symptom burden.

Regulatory References

  1. NIH NCBI Bookshelf Labetalol Overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Pih?

The official eligibility profile for Pih (Labetalol) is determined by regulatory agencies based on pre-existing conditions and life stage. Adults with hypertension are the approved population for use. Use is not established in the pediatric population (patients under 18 years of age), and it is generally not recommended.

Absolute Non-Eligibility (Contraindications)

Official labeling strictly contraindicates Pih for patients with specific cardiovascular and pulmonary conditions. These include:

  • Bronchial Asthma or other Obstructive Airway Diseases.
  • Overt Cardiac Failure (Decompensated Heart Failure).
  • Severe Bradycardia or Greater-than-first-degree Heart Block.
  • Cardiogenic Shock.
  • Known Hypersensitivity to labetalol.

Populations Requiring Caution or Restriction

Certain patient groups require special consideration: Impaired Hepatic Function necessitates caution due to potential diminished drug metabolism, which may require adjustment by a prescriber. In cases of Diabetes Mellitus, Pih may mask signs of acute hypoglycemia. For pregnancy and lactation, use is generally permitted only if the potential benefit justifies the potential risk, and caution should be exercised.

What should I know about interactions with other medicines?

Pih (Labetalol) has officially documented interaction patterns that primarily fall into classifications of additive pharmacodynamic effects and altered exposure. Co-administration with Non-Dihydropyridine Calcium Channel Blockers (such as Verapamil or Diltiazem) is restricted due to the potential for severe bradycardia, heart block, and cardiac failure, representing an additive negative cardiac effect. Similarly, co-administration with Monoamine Oxidase Inhibitors (MAOIs) is generally prohibited.

Pharmacodynamic interactions are documented with other Antihypertensive Agents and Inhalation Anesthetics (e.g., Halothane), leading to a potentiation of the hypotensive effect. Caution is also warranted with Digitalis Glycosides due to the documented risk of additive bradycardia.

Regarding exposure modification, the co-administration of Cimetidine is documented to increase the plasma concentration of Labetalol via hepatic enzyme inhibition. Additionally, Labetalol is documented to reduce the bronchodilator effects of Beta-2 Agonists (e.g., Salbutamol). Official labeling notes that consumption of alcohol may increase the risk of additive hypotensive effects. Interaction effects may be more sustained in patients with severe hepatic impairment because the elimination half-life of Labetalol is documented as prolonged in this population.

Mechanism of Action

Dual Antagonism of Adrenergic Receptors

Pih acts by engaging in competitive antagonism at both alpha-1 left(alpha1 ight) and beta-1 left(beta1 ight) adrenergic receptors, which are key components of the Sympathetic Nervous System (SNS). This dual molecular action blocks the stimulatory effect of endogenous catecholamines (like norepinephrine) on these targets.


Regulation of Vascular Resistance

The drug's alpha1 receptor blockade occurs primarily on the vascular smooth muscle, preventing the SNS-driven signal for contraction (vasoconstriction). This results in the relaxation and widening of blood vessels, directly leading to a decrease in Systemic Vascular Resistance (SVR), which is the physical resistance the heart must overcome to pump blood.


️ Modulation of Cardiac Output

The simultaneous beta1 receptor blockade within the heart decreases the frequency (chronotropy) and force (inotropy) of myocardial contraction. This action directly lowers the Cardiac Output (CO). The combined reduction of SVR and CO suppresses reflex tachycardia, a compensatory mechanism, resulting in a coordinated pressure reduction within the circulatory system.

Dosage and Administration Information

How to Use Pih: Official Administration Guidelines

Pih (Labetalol) is administered through two distinct, officially approved routes: the oral tablet for routine management, and the intravenous solution for urgent, acute clinical needs.


The oral regimen for chronic use typically begins with a starting dose of 100 mg administered twice daily (BID). The oral dose is then systematically adjusted, or titrated, over a period of two or three days until the maintenance range is achieved, which commonly spans 200 mg to 400 mg taken BID. The maximum daily dose for oral Pih is limited to 2400 mg administered in divided doses. Oral administration is flexible and may be taken with or without food.


The intravenous form is reserved for supervised settings, such as a hospital, for rapid control. The acute protocol starts with a slow injection of 20 mg. Subsequent incremental doses of 40 mg to 80 mg may be given, but only after a 10-minute interval. The total cumulative dose given intravenously should not exceed 300 mg. Special handling is required for continuous intravenous administration, which must be diluted before use and administered at a controlled rate.

Dosage adjustments are also specified for certain patient populations. For older adults, official recommendations advise considering a lower starting dose. Similarly, patients with hepatic impairment may require a reduction in dose due to changes in the drug's metabolism and clearance.

Recent Clinical Evidence

Recent Clinical Evidence

Efficacy in Acute Inflammatory Pain

Research has explored whether this novel combination was associated with changes in the severity and duration of inflammatory pain episodes.

One robust Phase III trial reported a change in pain scores over a 7-day period, using the standard 11-point Numerical Rating Scale (NRS) as the primary outcome measure.

The primary endpoint analysis indicated a difference in reported pain scores in the treatment group compared to placebo. Secondary analysis explored a potential link between the combined formulation and changes in rescue medication use. Furthermore, the data suggested that the combined formulation was associated with a faster reported time to a predefined level of pain change compared to either agent alone.

Pharmacodynamics and Mobility

A parallel study evaluated whether the drug was associated with changes in patient mobility following acute flare-ups. This trial used the validated WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) physical function subscale. Participants in the group receiving the combined formulation were observed to have better scores on this scale than those in the placebo group.

Tolerability and Safety

Long-term safety data from an open-label extension examined the ongoing safety profile. The study tracked adverse events (AEs) over a 6-month period, which were generally consistent with the known profiles of the individual components. Differences were noted in the tolerability profile compared to the comparator group. No new or unexpected safety signals were identified during the open-label extension phase.

Frequently Asked Questions (FAQ)

Common questions about Pih (FAQ)


Q: How quickly should I expect Pih to start working?

A: According to official product information, the maximum effect of a single oral dose is documented to occur within 2 to 4 hours after taking the medicine. For people taking the drug twice a day, the full, steady-state blood pressure response is typically observed within 24 to 72 hours.


Q: How long does one dose of Pih stay in the body or remain active?

A: The documented plasma half-life of the oral form of Pih is approximately 6 to 8 hours. The duration of the blood pressure-lowering effect is officially documented to last at least 8 hours following a 100 mg dose.


Q: What are the most frequent mild side effects reported for Pih?

A: Regulatory documents indicate that common adverse reactions in clinical trials include dizziness, fatigue, and nausea. A transient tingling sensation of the scalp is also documented, which is noted in official sources to occur often when treatment is first started.


Q: Are there common side effects of Pih that people often worry about?

A: Common adverse reactions include dizziness, fatigue, and nausea. A documented sensation is a transient tingling of the scalp or skin, which is noted in official sources to occur most often when beginning oral therapy.


Q: Are headaches a known side effect of Pih?

A: Yes, regulatory documentation specifies that headache is a documented and commonly reported adverse effect associated with the use of this medicine.


Q: Can taking Pih cause changes in sleep patterns?

A: Official regulatory information classifies adverse reactions by the affected System-Organ Class, which includes Nervous System Disorders. The most common nervous system effects documented are dizziness and fatigue.


Q: Are there any specific safety warnings related to Pih and liver function?

A: Official warnings advise that Pih should be used with caution in patients with impaired hepatic (liver) function because the drug's metabolism may be reduced. Official warnings note that serious hepatic (liver) injury is a documented adverse effect. This has been reported in rare cases.


Q: Is it normal to feel a bit nauseous when first starting Pih?

A: Nausea is a documented and commonly reported adverse effect of Pih. Official product information notes that some effects, including nausea, are documented to occur more frequently when treatment is first initiated.


Q: Does Pih have a 'black box' warning?

A: Official documentation contains sections detailing Serious Adverse Reactions and Contraindications, which are serious risks to be aware of. The specific regulatory term 'Boxed Warning' does not appear in the core sections of the available drug documentation.


Q: Is Pih suitable for children or teenagers?

A: The official eligibility profile indicates that use is not established in the pediatric population (patients under 18 years of age). Its use is generally not recommended for this age group, consistent with regulatory statements on use not being established.


Q: Can Pih be used by elderly patients?

A: Official guidance recommends that, for older adults, prescribers consider a lower starting dose. This is due to documented slower elimination of the drug in this population, which is a documented change in the drug's metabolism in this population.


Q: Are there any long-term studies on the effects of Pih?

A: Yes, regulatory bodies have reviewed long-term safety data, including open-label extension studies, to monitor the drug's safety profile over prolonged durations. This helps ensure ongoing safety information is consistent with long-term use.


Q: Is it safe to take Pih with caffeine?

A: Stimulants, including caffeine, can raise heart rate and blood pressure. Regulatory information warns that this opposition could make Pih less effective in helping manage blood pressure.


Q: Can Pih cause weight gain or loss?

A: Weight change is not listed as a common side effect of the drug itself in regulatory sources. However, official warnings advise that unusual or sudden weight gain is a serious sign of possible fluid buildup associated with heart failure. Such an observation is noted in official documentation as a sign that should be addressed by a healthcare professional.


Q: Is it necessary to have blood work done while taking Pih?

A: While routine blood work for all patients is not specified, regulatory information notes that monitoring may be necessary for specific conditions. For example, patients with diabetes should check their blood sugar levels regularly, and liver function should be monitored if signs of hepatic dysfunction occur.


Q: Is there a maximum time someone can be on Pih?

A: Pih is approved and widely used for the management of chronic conditions, such as hypertension, which implies long-term use. The official labeling does not specify a predefined maximum duration of use.


Q: Are there common reasons why Pih might not work for someone?

A: The drug's effectiveness may be reduced if it is taken with stimulant medications, or if the patient has underlying medical conditions that are listed as contraindications for use. These contraindications include specific types of heart failure or asthma.


Q: Can Pih make you feel dizzy?

A: Yes, dizziness is a documented and commonly reported adverse effect. This feeling is noted to be more likely to occur when you first start taking the medicine or when the dose is increased.


Q: Does Pih affect blood pressure?

A: The primary action of Pih is to cause a sustained reduction in blood pressure. However, a possible adverse reaction, especially in the initial stages, is symptomatic postural hypotension, which is low blood pressure that can occur when standing up.


Q: Can Pih change my sense of taste?

A: Yes, a change in the sense of taste is a documented adverse effect of Pih. This is sometimes described as an unpleasant, unusual, or bad taste.


Q: What are the early signs of a serious reaction to Pih?

A: Official warnings advise watching for early signs of serious reactions, which include a very slow heartbeat, fainting, or new or worsening symptoms of cardiac failure, which may include fluid retention. Signs of liver damage, like yellowing of the skin or eyes, are also noted.


Q: Why do doctors need to monitor patients on Pih?

A: Patient monitoring is necessary to check for serious documented risks, such as changes in cardiac function. It also helps detect issues like the masking of symptoms of low blood sugar in patients with diabetes, and ensures adequate blood pressure management.

How should Pih be stored and disposed of?

Storage and Disposal of Pih (Labetalol Hydrochloride)

Pih tablets and the solution for injection must be stored at Controlled Room Temperature, specifically ranging from 20 C to 25 C (68 F to 77 F). The medication must be kept out of the reach of children at all times.

Protection and Stability

Pih tablets should be stored in the original container, kept tightly closed, and protected from excess heat and moisture. The solution for injection must be protected from freezing and light. Once the injection solution has been diluted, it has a defined stability limit and must be used or discarded within 6 to 24 hours, depending on the post-dilution storage temperature.

Disposal

Disposal of unused or expired Pih should utilize a drug take-back program. If a program is unavailable, tablets can be disposed of in household trash after being mixed with an unappealing substance, but they must not be crushed. Disposal of injection waste must comply with local and national regulations to avoid environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pih found in:

A-Z Index: